Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Starts China Bridging Trial of GIST Candidate

publication date: Jul 10, 2019

CStone Pharma of Suzhou has dosed the first patient in a China clinical trial of avapritinib as a treatment for gastrointestinal stromal tumors (GIST). One year ago, CStone acquired China rights to the candidate from Blueprint Medicines of Boston in a three-drug deal worth up to $386 million. CStone is conducting a Phase I/III bridging trial that will be part of Blueprint's global Phase III trial of avapritinib as a third/fourth line treatment for GIST, compared to Bayer's Stivarga® (regorafenib). More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.